Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Vifor Pharma    VIFN   CH0364749348

VIFOR PHARMA

(VIFN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
188(c) 177.6(c) 180.25(c) 181.15(c) 181.1(c) Last
99 755 488 782 264 977 242 093 187 927 Volume
-0.24% -5.53% +1.49% +0.50% -0.03% Change
More quotes
Financials (CHF)
Sales 2019 1 895 M
EBIT 2019 311 M
Net income 2019 145 M
Debt 2019 136 M
Yield 2019 1,13%
Sales 2020 2 102 M
EBIT 2020 469 M
Net income 2020 294 M
Finance 2020 148 M
Yield 2020 1,10%
P/E ratio 2019 79,1x
P/E ratio 2020 39,3x
EV / Sales2019 6,27x
EV / Sales2020 5,52x
Capitalization 11 743 M
More Financials
Company
Vifor Pharma specializes in the research, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency and nephrological and cardiovascular disorders. Vitor Pharma also markets a diversified portfolio of prescription drugs and OTC products. At the end of... 
Sector
Pharmaceuticals
Calendar
03/12Earnings Release
More about the company
Surperformance© ratings of Vifor Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on VIFOR PHARMA
02/20Fresenius forecasts 2020 profit growth driven by drug, dialysis units
RE
02/20Fresenius 4Q Net Profit Flat; Creates JV With Vifor in China
DJ
02/20VIFOR PHARMA : and Fresenius Kabi create joint venture in China for i.v. iron po..
BU
02/17VIFOR PHARMA : acquires Priority Review Voucher
BU
2019CHEMOCENTRYX : Vifor Pharma - VFMCRP and ChemoCentryx announce positive topline ..
AQ
2019EUROPE : Positive trade sentiment nudges European stocks higher
RE
2019VIFOR PHARMA : raises awareness on Iron Deficiency Day 2019 for people around th..
BU
2019VIFOR PHARMA : Appoints Lee Heeson as President International and Member of the ..
BU
2019CHEMOCENTRYX : Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoC..
AQ
2019VIFOR PHARMA : and Evotec form joint venture for early development in nephrology
BU
2019GLOBAL MARKETS LIVE : PSA, Fiat Chrysler, Fitbit, McDonald’s…
2019VIFOR PHARMA : Enters Into Commercial Collaboration in the US with Janssen
BU
2019VIFOR PHARMA : Appoints New Chief Medical Officer and Announces Changes to Execu..
BU
2019VIFOR PHARMA : announces the initiation of S&P credit rating coverage with an in..
BU
2019GLOBAL MARKETS LIVE : Uber, Broadcom, Carlsberg, Salesforce…
More news
News in other languages on VIFOR PHARMA
02/21ZURICH STOCK EXCHANGE : 4-Wochenvorschau Schweiz
02/20Aktien Schweiz Schluss: Korrektur auf hohem Niveau - Swiss Re schwach
02/20Principales informations avant-Bourse
02/20Vifor Pharma et Fresenius Kabi fondent une entreprise commune en Chine
02/20Vifor Pharma und Fresenius Kabi gründen JV in China für Eisen-Portfolio
More news
Analyst Recommendations on VIFOR PHARMA
More recommendations
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart VIFOR PHARMA
Duration : Period :
Vifor Pharma Technical Analysis Chart | VIFN | CH0364749348 | MarketScreener
Technical analysis trends VIFOR PHARMA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 174,08  CHF
Last Close Price 181,10  CHF
Spread / Highest target 13,2%
Spread / Average Target -3,87%
Spread / Lowest Target -33,7%
EPS Revisions
Managers
NameTitle
Gianni Zampieri Chief Executive Officer & Director
Stefan Schulze President & Chief Operating Officer
Etienne Jornod Executive Chairman
Colin Bond Chief Financial Officer
Klaus Henning Jensen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA2.55%12 004
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679